

Author index

Volume 126 (1996)

- Alam, R., S. Kataoka, S. Alam, F. Yatsu, Inhibition of vascular smooth muscle cell proliferation by the calcium antagonist clentiazem: role of protein kinase C **126**, 207
- Alam, S., see Alam, R. **126**, 207
- Alavi, M.Z., see Wang, H. **126**, 95
- Albanese, M., see Feussner, G. **126**, 177
- Alessandri, C., see Iuliano, L. **126**, 131
- Allegra, L., see Blasi, F. **126**, 341
- Arveiler, D., see Herrmann, S.-M. **126**, 299
- Arveiler, D., see Malinow, M.R. **126**, 27
- Aston, C.E., see Sanghera, D.K. **126**, 35
- Azzi, A., see Şirikçi, Ö. **126**, 253
- Bach, R.G., see Miller, D.D. **126**, 1
- Bailey, S.R., see Miller, D.D. **126**, 1
- Bard, J.-M., see Herrmann, S.-M. **126**, 299
- Barnes, J.F., see Farish, E. **126**, 77
- Blanc, H., see Herrmann, S.-M. **126**, 299
- Blann, A., J. Morris, C. McCollum, Soluble L-selectin in peripheral arterial disease: relationship with soluble E-selectin and soluble P-selectin **126**, 227
- Blasi, F., M.L. Ranzi, M. Erba, P. Tarsia, R. Racanelli, L. Fagetti, L. Allegra, No evidence for the presence of *Helicobacter pylori* in atherosclerotic plaques in abdominal aortic aneurysm specimens **126**, 341
- Blazek, I., see Leitinger, N. **126**, 305
- Bredie, S.J.H., J.M. Vogelaar, P.N.M. Demacker, A.F.H. Stalenhoef, Apolipoprotein E polymorphism influences lipid phenotypic expression, but not the low density lipoprotein subfraction distribution in familial combined hyperlipidemia **126**, 313
- Brown, A., see Farish, E. **126**, 77
- Brun, L.-D., see Torres, A.L. **126**, 163
- Bryan, N., see Zuckerman, S.H. **126**, 65
- Calder, A., see Farish, E. **126**, 77
- Camasta, C., see Iuliano, L. **126**, 131
- Cambien, F., see Herrmann, S.-M. **126**, 299
- Cambien, F., see Malinow, M.R. **126**, 27
- Cameron, J., see Sherrard, B. **126**, 277
- Camps, J., see Joven, J. **126**, 243
- Carriho, A.J.F., see Lottenberg, A.M.P. **126**, 265
- Chen, Q., see Stulnig, T.M. **126**, 85
- Colavita, A.R., see Iuliano, L. **126**, 131
- Dart, A., see Sherrard, B. **126**, 277
- de Almeida, E., see Jorge, P.A.R. **126**, 43
- Demacker, P.N.M., see Bredie, S.J.H. **126**, 313
- Derr, J., see Mustad, V. **126**, 117
- Després, J.-P., see Torres, A.L. **126**, 163
- Dubick, M.A., see Killion, S.L. **126**, 289
- Ducimetiere, P., see Malinow, M.R. **126**, 27
- Dzien, A., see Hoppichler, F. **126**, 333
- Endler, G., see Leitinger, N. **126**, 305
- Erba, M., see Blasi, F. **126**, 341
- Eskelson, C.D., see Killion, S.L. **126**, 289
- Espinell, E., see Joven, J. **126**, 243
- Evans, A.E., see Malinow, M.R. **126**, 27
- Evans, A., see Herrmann, S.-M. **126**, 299
- Fagetti, L., see Blasi, F. **126**, 341
- Farish, E., K. Spowart, J.F. Barnes, C.D. Fletcher, A. Calder, A. Brown, D.M. Hart, Effects of postmenopausal hormone replacement therapy on lipoproteins including lipoprotein(a) and LDL subfractions **126**, 77
- Farrar, M., see Miller, D.D. **126**, 1
- Feres, M.C., see Maranhão, R.C. **126**, 15
- Ferrell, R.E., see Sanghera, D.K. **126**, 35
- Feussner, G., M. Albanese, A. Valencia, Three-dimensional structure of the LDL receptor-binding domain of the human apolipoprotein E2 (Arg₁₃₆ → Cys) variant **126**, 177
- Fiorani, P., see Iuliano, L. **126**, 131
- Fletcher, C.D., see Farish, E. **126**, 77
- Folsom, A.R., see Iso, H. **126**, 233
- Frants, R.R., see Sijbrands, E.J.G. **126**, 197

- Gagné, C., see Torres, A.L. 126, 163
 Gevers Leuven, J.A., see Sijbrands, E.J.G. 126, 197
 Gianinni, S.D., see Maranhão, R.C. 126, 15
 Gotto, Jr, A.M., see Yang, C.-Y. 126, 105
 Gu, Z.-W., see Yang, C.-Y. 126, 105
 Gylling, H., T.A. Miettinen, Cholesterol absorption and lipoprotein metabolism in type II diabetes mellitus with and without coronary artery disease 126, 325
- Hall, K.A., see Killion, S.L. 126, 289
 Harada, S., see Iso, H. 126, 233
 Hart, D.M., see Farish, E. 126, 77
 Havekes, L.M., see Sijbrands, E.J.G. 126, 197
 Herrmann, S.-M., H. Blanc, O. Poirier, D. Arveiler, G. Luc, A. Evans, P. Marques-Vidal, J.-M. Bard, F. Cambien, The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study 126, 299
 Hintze, T.H., see Stephan, Z.F. 126, 53
 Hoffer, M.J.V., see Sijbrands, E.J.G. 126, 197
 Hoppichler, F., M. Lechleitner, C. Traweger, G. Schett, A. Dzien, W. Sturm, Q. Xu, Changes of serum antibodies to heat-shock protein 65 in coronary heart disease and acute myocardial infarction 126, 333
 Hornstra, G., see van de Vijver, L.P.L. 126, 155
 Hu, C.-W., see Stephan, Z.F. 126, 53
 Hunter, G.C., see Killion, S.L. 126, 289
- Iida, M., see Iso, H. 126, 233
 Iso, H., S. Harada, T. Shimamoto, A.R. Folsom, K. Koike, S. Sato, M. Iida, Y. Komachi, Polymorphism of the apolipoprotein B gene and blood lipid concentrations in Japanese and Caucasian population samples 126, 233
 Iuliano, L., A. Signore, S. Vallabjosula, A.R. Colavita, C. Camastra, G. Ronga, C. Alessandri, E. Sbarigia, P. Fiorani, F. Violi, Preparation and biodistribution of ^{99m}technetium labelled oxidized LDL in man 126, 131
- Jarosch, E., see Stulnig, T.M. 126, 85
 Jennings, G., see Sherrard, B. 126, 277
 Jingami, H., see Matsuoka, N. 126, 221
 Jorge, P.A.R., M.R. Osaki, E. de Almeida, L.C. Neto, K. Metz, Effects of vitamin E on endothelium-dependent coronary flow in hypercholesterolemic dogs 126, 43
 Joven, J., E. Espinel, J.M. Simó, E. Vilella, J. Camps, A. Oliver, The influence of hypoalbuminemia in the generation of nephrotic hyperlipidemia 126, 243
 Jürgens, G., see Stulnig, T.M. 126, 85
- Kamboh, M.I., see Sanghera, D.K. 126, 35
 Kataoka, S., see Alam, R. 126, 207
 Killion, S.L., G.C. Hunter, C.D. Eskelson, M.A. Dubick, C.W. Putnam, K.A. Hall, C.A. Luedke, R.L. Misorowski, J.D. Schilling, K.E. McIntyre, Vitamin E levels in human atherosclerotic plaque: the influence of risk factors 126, 289
 Kimm, S.Y.S., see Sanghera, D.K. 126, 35
- Kobayashi, K., see Taniguchi, S. 126, 143
 Koike, K., see Iso, H. 126, 233
 Komachi, Y., see Iso, H. 126, 233
 Kris-Etherton, P.M., see Mustad, V. 126, 117
 Kruysen, D.A.C.M., see van de Vijver, L.P.L. 126, 155
- Lamarche, B., see Torres, A.L. 126, 163
 Lechleitner, M., see Hoppichler, F. 126, 333
 Leitinger, N., C. Pirich, I. Blazek, G. Endler, H. Sinzinger, Decreased susceptibility of low-density lipoproteins to in-vitro oxidation after dextran-sulfate LDL-apheresis treatment 126, 305
 Leonards, K.S., see Stephan, Z.F. 126, 53
 Lottenberg, A.M.P., V.S. Nunes, S.A. Lottenberg, A.F.M. Shimabukuro, A.J.F. Carrilho, S. Malagutti, E.R. Nakanakare, R. McPherson, E.C.R. Quintão, Plasma cholesteryl ester synthesis, cholesteryl ester transfer protein concentration and activity in hypercholesterolemic women: effects of the degree of saturation of dietary fatty acids in the fasting and postprandial states 126, 265
 Lottenberg, S.A., see Lottenberg, A.M.P. 126, 265
 Luc, G., see Herrmann, S.-M. 126, 299
 Luc, G., see Malinow, M.R. 126, 27
 Luedke, C.A., see Killion, S.L. 126, 289
 Lupien, P.-J., see Torres, A.L. 126, 163
- Malagutti, S., see Lottenberg, A.M.P. 126, 265
 Malinow, M.R., P. Ducimetiere, G. Luc, A.E. Evans, D. Arveiler, F. Cambien, B.M. Upson, Plasma homocyst(e)ine levels and graded risk for myocardial infarction: findings in two populations at contrasting risk for coronary heart disease 126, 27
 Maranhão, R.C., M.C. Feres, M.T. Martins, C.H. Mesquita, O. Toffoletto, C.G.C. Vinagre, S.D. Gianinni, F. Pileggi, Plasma kinetics of a chylomicron-like emulsion in patients with coronary artery disease. 126, 15
 Marques-Vidal, P., see Herrmann, S.-M. 126, 299
 Martins, M.T., see Maranhão, R.C. 126, 15
 Masuzaki, H., see Matsuoka, N. 126, 221
 Matsuoka, N., H. Jingami, H. Masuzaki, M. Mizuno, S. Nakaishi, J. Suga, T. Tanaka, T. Yamamoto, K. Nakao, Effects of gemfibrozil administration on very low density lipoprotein receptor mRNA levels in rabbits 126, 221
 McAllister, A.E., see Sanghera, D.K. 126, 35
 McCollum, C., see Blann, A. 126, 227
 McIntyre, K.E., see Killion, S.L. 126, 289
 McPherson, R., see Lottenberg, A.M.P. 126, 265
 Meinders, A.E., see Sijbrands, E.J.G. 126, 197
 Mesquita, C.H., see Maranhão, R.C. 126, 15
 Metz, K., see Jorge, P.A.R. 126, 43
 Miettinen, T.A., see Gylling, H. 126, 325
 Miller, D.D., R.G. Bach, F.O. Tio, S.R. Bailey, C.A. Waters, T.G. Woodworth, J.C. Nichols, S.B. Paige, M. Farrar, Interleukin-2 receptor-specific fusion toxin inhibits barotrauma-induced arterial atherosclerosis 126, 1
 Misorowski, R.L., see Killion, S.L. 126, 289
 Mizuno, M., see Matsuoka, N. 126, 221

- Moll, D., see Stulnig, T.M. 126, 85
- Moore, S., see Wang, H. 126, 95
- Moorjani, S., see Torres, A.L. 126, 163
- Morris, J., see Blann, A. 126, 227
- Mourão, P.A.S., see Tovar, A.M.F. 126, 185
- Mustad, V., J. Derr, C.C. Reddy, T.A. Pearson, P.M. Kris-Etherton, Seasonal variation in parameters related to coronary heart disease risk in young men 126, 117
- Nakaishi, S., see Matsuoka, N. 126, 221
- Nakandakare, E.R., see Lottenberg, A.M.P. 126, 265
- Nakao, K., see Matsuoka, N. 126, 221
- Nawata, H., see Taniguchi, S. 126, 143
- Neto, L.C., see Jorge, P.A.R. 126, 43
- Nichols, J.C., see Miller, D.D. 126, 1
- Nunes, V.S., see Lottenberg, A.M.P. 126, 265
- Oliver, A., see Joven, J. 126, 243
- Osaki, M.R., see Jorge, P.A.R. 126, 43
- Özer, N.K., see Şirikçi, Ö. 126, 253
- Paige, S.B., see Miller, D.D. 126, 1
- Pearson, T.A., see Mustad, V. 126, 117
- Pileggi, F., see Maranhão, R.C. 126, 15
- Dirich, C., see Leitinger, N. 126, 305
- Poirier, O., see Herrmann, S.-M. 126, 299
- Putnam, C.W., see Killion, S.L. 126, 289
- Quintão, E.C.R., see Lottenberg, A.M.P. 126, 265
- Quion, J.A.V., see Yang, C.-Y. 126, 105
- Raccanelli, R., see Blasi, F. 126, 341
- Ranzi, M.L., see Blasi, F. 126, 341
- Reddy, C.C., see Mustad, V. 126, 117
- Ronga, G., see Iuliano, L. 126, 131
- Sanghera, D.K., R.E. Ferrell, C.E. Aston, A.E. McAllister, M.I. Kamboh, S.Y.S. Kimm, Quantitative effects of the apolipoprotein E polymorphism in a biracial sample of 9-10-year-old girls 126, 35
- Sato, S., see Iso, H. 126, 233
- Sbarigia, E., see Iuliano, L. 126, 131
- Schett, G., see Hoppichler, F. 126, 333
- Schilling, J.D., see Killion, S.L. 126, 289
- Schönitzer, D., see Stulnig, T.M. 126, 85
- Sharif, R., see Stephan, Z.F. 126, 53
- Sherrard, B., H. Simpson, J. Cameron, S. Wahi, G. Jennings, A. Dart, LDL particle size in subjects with previously unsuspected coronary heart disease: relationship with other cardiovascular risk markers 126, 277
- Shimabukuro, A.F.M., see Lottenberg, A.M.P. 126, 265
- Shimamoto, T., see Iso, H. 126, 233
- Signore, A., see Iuliano, L. 126, 131
- Sijbrands, E.J.G., R.G.J. Westendorp, M.J.V. Hoffer, R.R. Frants, A.E. Meinders, J.H.M. Souverein, J.A. Gevers Leuven, A. Van der Laarse, L.M. Havekes, A.H.M. Smelt, Effect of apolipoprotein E and insulin resistance on VLDL particles in combined hyperlipidemic patients 126, 197
- Simó, J.M., see Joven, J. 126, 243
- Simpson, H., see Sherrard, B. 126, 277
- Sinzinger, H., see Leitinger, N. 126, 305
- Şirikçi, Ö., N.K. Özer, A. Azzi, Dietary cholesterol-induced changes of protein kinase C and the effect of vitamin E in rabbit aortic smooth muscle cells 126, 253
- Smelt, A.H.M., see Sijbrands, E.J.G. 126, 197
- Souverijn, J.H.M., see Sijbrands, E.J.G. 126, 197
- Spowart, K., see Farish, E. 126, 77
- Stalenhoef, A.F.H., see Bredie, S.J.H. 126, 313
- Steele, R.E., see Stephan, Z.F. 126, 53
- Stephan, Z.F., E.C. Yurachek, R. Sharif, J.M. Wasvary, K.S. Leonards, C.-W. Hu, T.H. Hintze, R.E. Steele, Demonstration of potent lipid-lowering activity by a thymimetic agent devoid of cardiovascular and thermogenic effects 126, 53
- Stulnig, T.M., G. Jürgens, Q. Chen, D. Moll, D. Schönitzer, E. Jarosch, G. Wick, Properties of low density lipoproteins relevant to oxidative modifications change paradoxically during aging 126, 85
- Sturm, W., see Hoppichler, F. 126, 333
- Suga, J., see Matsuoka, N. 126, 221
- Takayanagi, R., see Taniguchi, S. 126, 143
- Tanaka, T., see Matsuoka, N. 126, 221
- Taniguchi, S., T. Yanase, K. Kobayashi, R. Takayanagi, H. Nawata, Dehydroepiandrosterone markedly inhibits the accumulation of cholesteryl ester in mouse macrophage J774-1 cells 126, 143
- Tarsia, P., see Blasi, F. 126, 341
- Tio, F.O., see Miller, D.D. 126, 1
- Toffoletto, O., see Maranhão, R.C. 126, 15
- Torres, A.L., S. Moorjani, M.-C. Vohl, C. Gagné, B. Lamarche, L.-D. Brun, P.-J. Lupien, J.-P. Després, Heterozygous familial hypercholesterolemia in children: low-density lipoprotein receptor mutational analysis and variation in the expression of plasma lipoprotein-lipid concentrations. 126, 163
- Tovar, A.M.F., P.A.S. Mourão, High affinity of a fucosylated chondroitin sulfate for plasma low density lipoprotein 126, 185
- Traweger, C., see Hoppichler, F. 126, 333
- Upson, B.M., see Malinow, M.R. 126, 27
- Valencia, A., see Feussner, G. 126, 177
- Valentinova, N.V., see Yang, C.-Y. 126, 105
- Vallabajosula, S., see Iuliano, L. 126, 131
- Van der Laarse, A., see Sijbrands, E.J.G. 126, 197
- van de Vijver, L.P.L., G. van Poppel, A. van Houwelingen, D.A.C.M. Kruysen, G. Hornstra, Trans unsaturated fatty acids in plasma phospholipids and coronary heart disease: a case-control study 126, 155
- van Houwelingen, A., see van de Vijver, L.P.L. 126, 155

- van Pöppel, G., see van de Vijver, L.P.L. 126, 155
Vilella, E., see Joven, J. 126, 243
Vinagre, C.G.C., see Maranhão, R.C. 126, 15
Violi, F., see Iuliano, L. 126, 131
Vogelaar, J.M., see Bredie, S.J.H. 126, 313
Vohl, M.-C., see Torres, A.L. 126, 163

Wahi, S., see Sherrard, B. 126, 277
Wang, H., S. Moore, M.Z. Alavi, Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP-1) in rabbit aortic neointima after selective de-endothelialization 126, 95
Wasvary, J.M., see Stephan, Z.F. 126, 53
Waters, C.A., see Miller, D.D. 126, 1
Westendorp, R.G.J., see Sijbrands, E.J.G. 126, 197
Wick, G., see Stulnig, T.M. 126, 85
Woodworth, T.G., see Miller, D.D. 126, 1

Xie, Y.-H., see Yang, C.-Y. 126, 105

Xu, Q., see Hoppichler, F. 126, 333

Yamamoto, T., see Matsuoka, N. 126, 221
Yanase, T., see Taniguchi, S. 126, 143
Yang, C.-Y., Z.-W. Gu, Y.-H. Xie, N.V. Valentinova, M. Yang, D. Yeshurun, J.A.V. Quion, A.M. Gotto, Jr, Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia 126, 105
Yang, M., see Yang, C.-Y. 126, 105
Yatsu, F., see Alam, R. 126, 207
Yeshurun, D., see Yang, C.-Y. 126, 105
Yurachek, E.C., see Stephan, Z.F. 126, 53

Zuckerman, S.H., N. Bryan, Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL) 126, 65

Subject index

Volume 126 (1996)

- Abdominal aortic aneurysm 126, 341
 Acetylcholine 126, 43
 African American disease risk 126, 35
 Aging 126, 85
 Angioplasty 126, 1
 Antibodies 126, 333
 Anti-oxidants 126, 85
 Apo B gene 126, 233
 ApoE 126, 197
 Apo E2 (Arg₁₃₆ → Cys) 126, 177
 Apolipoprotein A-I 126, 117
 Apolipoprotein B100 126, 117
 Apolipoprotein E 126, 35, 105, 177
 Apolipoprotein E polymorphism 126, 313
 Atherosclerosis 126, 1, 53, 85, 95, 131, 207, 227, 253, 299, 305, 333
 Atherosclerotic risk factors 126, 289
 Blood total cholesterol 126, 233
 Calcium antagonist 126, 207
 Children 126, 163
 Cholesterol 126, 15, 53
 Cholesterol absorption and synthesis 126, 325
 Cholesterol esterification 126, 143
 Cholesterol ester reduction 126, 143
 Cholesteryl ester cycle 126, 143
 Cholesteryl ester storage 126, 143
 Cholesteryl ester transfer protein 126, 265
 Chondroitin 6-sulfate 126, 185
 Chylomicrons 126, 15
 Clonazepam 126, 207
 Combined hyperlipidemia 126, 197
 Coronary artery disease 126, 15, 325
 Coronary atherosclerosis 126, 155
 Coronary heart disease 126, 27, 277, 333, 341
 Coronary risk factors 126, 233
 Cross-cultural comparison 126, 233
 Cytokines 126, 1
 Cytotoxic therapy 126, 1
 Dehydroepiandrosterone (DHEA) 126, 143
 Dextrane-sulfate LDL-apheresis 126, 305
 DHEA analogue 126, 143
 Dog 126, 43
 Dominant mode of inheritance 126, 177
 Dysbetalipoproteinemia 126, 177
 Emulsions 126, 15
 Endothelium-dependent coronary flow 126, 43
 Extracellular matrix 126, 95
 Familial combined hyperlipidemia 126, 313
 Familial hypercholesterolemia 126, 163
 Free radicals 126, 131
 Fucans 126, 185
 Fucosylated chondroitin sulfate 126, 185
 Fusion toxin 126, 1
 Gemfibrozil 126, 105, 221
 Gene expression 126, 95
 Genetic epidemiology 126, 163
 Genetic polymorphism 126, 35
 Genetics 126, 313
 Glucose 126, 277
 Glycosaminoglycans 126, 185
 Heat shock proteins 126, 333
Helicobacter pylori 126, 341
 Heparin 126, 185
 Hormone replacement 126, 77
 Hypercholesterolemia 126, 43, 265
 Hyperinsulinemia 126, 197
 Hyperlipidemia 126, 105, 243
 Hypertension 126, 207
 Hypoalbuminemia 126, 243
 Hypolipidemic 126, 53
 Imaging 126, 131
 Injury 126, 95
 In situ hybridization 126, 95

- Insulin 126, 277
Interleukin-2 126, 1
Isoprostanes 126, 305

6-keto-PGF_{1 α} 126, 117

LDL 126, 53, 185
LDL and HDL kinetics 126, 325
LDL-biodistribution 126, 131
LDL-cholesterol 126, 35
LDL-oxidation 126, 305
LDL-receptor gene 126, 163
LDL size 126, 105
LDL subfractions 126, 77
Lecithin-cholesterol-acyl transferase 126, 265
Lipid peroxidation 126, 85
Lipid peroxides 126, 289
Lipoperoxides 126, 65
Lipoprotein(a) 126, 77
Lipoproteins 126, 15, 77, 131, 185, 243
Low density lipoprotein particle size 126, 277
Low density lipoproteins 126, 65
Low-density lipoproteins (LDL) 126, 85
L-T₃ 126, 53
lysosomal cholesterol transport 126, 143

Macrophages 126, 65
Membranous nephropathy 126, 243
Myocardial infarction 126, 27, 299, 333

Nephrotic syndrome 126, 243

Oncotic pressure 126, 243
Oxidation 126, 65
Oxidized-LDL 126, 131

Paraoxonase 126, 299
Particle size 126, 197
Phagocytosis 126, 65
Phenotypic expression 126, 313

Phospholipids 126, 155
Plant sterols 126, 325
Plasma homocyst(e)ine 126, 27
Plasma lipoproteins 126, 35, 105
Polymorphism 126, 233, 299
Polyunsaturated fatty acids 126, 85, 265
Postmenopausal 126, 77
Proliferation 126, 207
Protein kinase C 126, 207, 253
Proteinuria 126, 243

Rabbit 126, 221
Risk factors 126, 27
RT-PCR 126, 95

Saturated fatty acids 126, 265
Seasonal variation 126, 117
SENIEUR protocol 126, 85
Smooth muscle cells 126, 207, 253
Sodium nitroprusside 126, 43
Soluble E-selectin 126, 227
Soluble L-selectin 126, 227
Soluble P-selectin 126, 227
Sulfated polysaccharides 126, 185

Thiobarbituric acid reactive substances 126, 305
Thyromimetic 126, 53
TIMP 126, 95
Trans fatty acid 126, 155
Triglyceride 126, 277
Triglycerides 126, 15
TXB₂ 126, 117
Type II diabetes mellitus 126, 325
Type III hyperlipoproteinemia 126, 177

Vitamin E 126, 43, 253, 289
VLDL 126, 197
VLDL composition 126, 105
VLDL receptor 126, 221
VLDL subfractions 126, 105

